Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Human Immunodeficiency Virus | Methodology

Development and evaluation of serological screening based on one dried plasma spot for HIV, syphilis, and HCV

Authors: Jie-qiong Ma, Ya-nan Ren, Shi-yuan Wen, Ao-bo Dong, Wen-ge Xing, Yan Jiang

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

In the effort to prevent and control HIV/AIDS, China has established a national sentinel surveillance system. However, some sentinel sites face limitations in environmental resources and accessibility, prompting the exploration of alternative sample strategies. Dried plasma spots (DPS) samples are viewed as promising alternatives to traditional plasma samples due to their advantages, including sample stability, easy storage, and convenient transport. This study aims to develop a method for screening HIV, Treponema pallidum (TP), and Hepatitis C Virus (HCV) using DPS samples and assess their performance.

Methods

Based on existing commercial assay kits, a detection method was established through the optimization of experimental parameters, including the amount of plasma on filter paper, the volume of elution solution applied to dried plasma spots, the size of dried plasma spots, elution solution volume, elution solution components, elution temperature, and elution time. A series of laboratory evaluation panels were constructed for laboratory assessments, including the laboratory basic panel, laboratory interference panel, and laboratory precision panel. Additionally, clinical samples were used for evaluation.

Results

Optimal conditions for DPS sample extraction were: plasma volume, 100 µL; DPS size, whole spot; eluent volume, 500 µL; eluent, PBS with 1‰ Tween20; elution time, 2 h; elution temperature, room temperature. A total of 619 paired plasma/DPS samples were tested by both methods. The DPS-based ELISA method exhibited 100% sensitivity/specificity for HIV, 98.6%/100% for TP, and 99.6%/100% for HCV. Kappa values between the plasma samples and DPS samples were 100% for HIV, 99% for TP, and 100% for HCV. The DPS-based ELISA method failed to detect 1 HCV mono-infected sample and TP in 1 HIV/HCV/TP co-infected sample. For the HIV/HCV/TP co-infected sample, the S/CO in the plasma sample was 2.143 and in the DPS sample was 0.5. For HCV, the S/CO (sample OD/cut-off) was 3.049 in the plasma sample and 0.878 in the DPS sample.

Conclusions

A single DPS, following one-time standardized processing, can be used to detect HIV, HCV, and TP. Researching and establishing laboratory testing methods better suited for China's sentinel surveillance have significant practical applications in improving HIV testing in resource-constrained environments.
Literature
3.
go back to reference Vazquez-Moron S, Ryan P, Ardizone-Jimenez B, et al. Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Sci Rep. 2018;8(1):1858.CrossRefPubMedPubMedCentral Vazquez-Moron S, Ryan P, Ardizone-Jimenez B, et al. Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Sci Rep. 2018;8(1):1858.CrossRefPubMedPubMedCentral
4.
go back to reference Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65(1 Suppl):S46-s66.CrossRefPubMed Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65(1 Suppl):S46-s66.CrossRefPubMed
6.
go back to reference Osteresch B, Viegas S, Cramer B, et al. Multi-mycotoxin analysis using dried blood spots and dried serum spots. Anal Bioanal Chem. 2017;409(13):3369–82.CrossRefPubMedPubMedCentral Osteresch B, Viegas S, Cramer B, et al. Multi-mycotoxin analysis using dried blood spots and dried serum spots. Anal Bioanal Chem. 2017;409(13):3369–82.CrossRefPubMedPubMedCentral
7.
go back to reference Hauser A, Meixenberger K, Machnowska P, et al. Robust and sensitive subtype-generic HIV-1 pol genotyping for use with dried serum spots in epidemiological studies. J Virol Methods. 2018;259:32–8.CrossRefPubMed Hauser A, Meixenberger K, Machnowska P, et al. Robust and sensitive subtype-generic HIV-1 pol genotyping for use with dried serum spots in epidemiological studies. J Virol Methods. 2018;259:32–8.CrossRefPubMed
8.
go back to reference Garcia-Lerma JG, McNulty A, Jennings C, et al. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother. 2009;64(1):33–6.CrossRefPubMedPubMedCentral Garcia-Lerma JG, McNulty A, Jennings C, et al. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother. 2009;64(1):33–6.CrossRefPubMedPubMedCentral
9.
go back to reference Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47(4):1107–18.CrossRefPubMedPubMedCentral Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47(4):1107–18.CrossRefPubMedPubMedCentral
10.
go back to reference Calcagno A, Motta I, Milia MG, et al. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. Br J Clin Pharmacol. 2015;79(5):801–8.CrossRefPubMedPubMedCentral Calcagno A, Motta I, Milia MG, et al. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. Br J Clin Pharmacol. 2015;79(5):801–8.CrossRefPubMedPubMedCentral
11.
go back to reference Knuchel MC, Tomasik Z, Speck RF, et al. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol. 2006;36(1):64–7.CrossRefPubMed Knuchel MC, Tomasik Z, Speck RF, et al. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol. 2006;36(1):64–7.CrossRefPubMed
12.
go back to reference Tonby K, Ruhwald M, Kvale D, et al. IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Sci Rep. 2015;5:9223.CrossRefPubMedPubMedCentral Tonby K, Ruhwald M, Kvale D, et al. IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Sci Rep. 2015;5:9223.CrossRefPubMedPubMedCentral
13.
go back to reference Heinig K, Bucheli F, Hartenbach R, et al. Determination of mycophenolic acid and its phenyl glucuronide in human plasma, ultrafiltrate, blood DBS and dried plasma spots. Bioanalysis. 2010;2(8):1423–35.CrossRefPubMed Heinig K, Bucheli F, Hartenbach R, et al. Determination of mycophenolic acid and its phenyl glucuronide in human plasma, ultrafiltrate, blood DBS and dried plasma spots. Bioanalysis. 2010;2(8):1423–35.CrossRefPubMed
14.
go back to reference Dwivedi J, Namdev KK, Chilkoti DC, et al. An improved LC-ESI-MS/MS method to quantify pregabalin in human plasma and dry plasma spot for therapeutic monitoring and pharmacokinetic applications. Ther Drug Monit. 2018;40(5):610–9.CrossRefPubMed Dwivedi J, Namdev KK, Chilkoti DC, et al. An improved LC-ESI-MS/MS method to quantify pregabalin in human plasma and dry plasma spot for therapeutic monitoring and pharmacokinetic applications. Ther Drug Monit. 2018;40(5):610–9.CrossRefPubMed
15.
go back to reference Enagnon Kazali A, Donatien M, Famara S, et al. Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville. Diagn Microbiol Infect Dis. 2014;78(3):229–31.CrossRef Enagnon Kazali A, Donatien M, Famara S, et al. Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville. Diagn Microbiol Infect Dis. 2014;78(3):229–31.CrossRef
16.
go back to reference Geretti AM, King S, Adjei-Asante K, et al. Hepatitis C Virus (HCV) RNA screening and sequencing using dry plasma spots. J Clin Virol. 2017;97:18–21.CrossRefPubMed Geretti AM, King S, Adjei-Asante K, et al. Hepatitis C Virus (HCV) RNA screening and sequencing using dry plasma spots. J Clin Virol. 2017;97:18–21.CrossRefPubMed
17.
go back to reference van Loo IHM, Dukers-Muijrers N, Heuts R, et al. Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling. PLoS ONE. 2017;12(10): e0186722.CrossRefPubMedPubMedCentral van Loo IHM, Dukers-Muijrers N, Heuts R, et al. Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling. PLoS ONE. 2017;12(10): e0186722.CrossRefPubMedPubMedCentral
18.
go back to reference Kania D, Bekale AM, Nagot N, et al. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso. West Africa Clin Microbiol Infect. 2013;19(12):E533–41.CrossRefPubMed Kania D, Bekale AM, Nagot N, et al. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso. West Africa Clin Microbiol Infect. 2013;19(12):E533–41.CrossRefPubMed
19.
go back to reference McDade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography. 2007;44(4):899–925.CrossRefPubMed McDade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography. 2007;44(4):899–925.CrossRefPubMed
20.
go back to reference Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49–65.CrossRefPubMed Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49–65.CrossRefPubMed
21.
go back to reference Antunes MV, Charao MF, Linden R. Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring. Clin Biochem. 2016;49(13–14):1035–46.CrossRefPubMed Antunes MV, Charao MF, Linden R. Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring. Clin Biochem. 2016;49(13–14):1035–46.CrossRefPubMed
22.
go back to reference Andriamandimby SF, Heraud JM, Randrianasolo L, et al. Dried-blood spots: a cost-effective field method for the detection of Chikungunya virus circulation in remote areas. PLoS Negl Trop Dis. 2013;7: e2339.CrossRefPubMedPubMedCentral Andriamandimby SF, Heraud JM, Randrianasolo L, et al. Dried-blood spots: a cost-effective field method for the detection of Chikungunya virus circulation in remote areas. PLoS Negl Trop Dis. 2013;7: e2339.CrossRefPubMedPubMedCentral
23.
go back to reference Villar LM, de Oliveira JC, Cruz HM, et al. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J Med Virol. 2011;83(9):1522–9.CrossRefPubMed Villar LM, de Oliveira JC, Cruz HM, et al. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J Med Virol. 2011;83(9):1522–9.CrossRefPubMed
24.
go back to reference Boons C, Timmers L, Janssen J, et al. Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling. Eur J Clin Pharmacol. 2019;75(6):825–9.CrossRefPubMed Boons C, Timmers L, Janssen J, et al. Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling. Eur J Clin Pharmacol. 2019;75(6):825–9.CrossRefPubMed
25.
go back to reference Lukacs Z, Nickel M, Murko S, et al. Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease. Clin Chim Acta. 2019;492:69–71.CrossRefPubMed Lukacs Z, Nickel M, Murko S, et al. Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease. Clin Chim Acta. 2019;492:69–71.CrossRefPubMed
26.
go back to reference Nguyen TT, Lemee V, Bollore K, et al. Confirmation of HCV viremia using HCV RNA and core antigen testing on dried blood spot in HIV infected peoples who inject drugs in Vietnam. BMC Infect Dis. 2018;18(1):622.CrossRefPubMedPubMedCentral Nguyen TT, Lemee V, Bollore K, et al. Confirmation of HCV viremia using HCV RNA and core antigen testing on dried blood spot in HIV infected peoples who inject drugs in Vietnam. BMC Infect Dis. 2018;18(1):622.CrossRefPubMedPubMedCentral
27.
go back to reference Smit PW, van der Vlis T, Mabey D, et al. The development and validation of dried blood spots for external quality assurance of syphilis serology. BMC Infect Dis. 2013;13:102.CrossRefPubMedPubMedCentral Smit PW, van der Vlis T, Mabey D, et al. The development and validation of dried blood spots for external quality assurance of syphilis serology. BMC Infect Dis. 2013;13:102.CrossRefPubMedPubMedCentral
28.
go back to reference Desbois D, Roque-Afonso AM, Lebraud P, et al. Use of dried serum spots for serological and molecular detection of hepatitis a viru. J Clin Microbiol. 2009;47(5):1536–42.CrossRefPubMedPubMedCentral Desbois D, Roque-Afonso AM, Lebraud P, et al. Use of dried serum spots for serological and molecular detection of hepatitis a viru. J Clin Microbiol. 2009;47(5):1536–42.CrossRefPubMedPubMedCentral
Metadata
Title
Development and evaluation of serological screening based on one dried plasma spot for HIV, syphilis, and HCV
Authors
Jie-qiong Ma
Ya-nan Ren
Shi-yuan Wen
Ao-bo Dong
Wen-ge Xing
Yan Jiang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02225-6

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.